CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week.  Topics include all stories related to hepatitis C  as well as personal stories and events.

HCV News

Week Ending 06/29/2015

AASLD updates guidance for use of hepatitis C drugs

‘The American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and in collaboration with the International Antiviral Society – USA (IAS-USA), created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 To aid practitioners treating patients infected with hepatitis C virus (CV).’

Editorial: Exchange program and awareness can fight hepatitis C

‘May was National Hepatitis Awareness Month. Turns out it came a month late to Madison County. Just last week, the county learned that it is on the verge of a hepatitis C epidemic. Kellie Kelley, public information officer for the Madison County Health Department, reported that in 2013 there were 70 new cases of hepatitis C identified in the county, and the number increased to 130 in 2014.’

Deep sequencing creates distinction between acute and chronic HCV

‘Deep sequencing accurately differentiated between acute and chronic hepatitis C virus infection, according to published study data. “Deep sequencing studies have demonstrated improved sensitivity for detection of minor sequence variants, compared to clonal sequencing, enabling highly sensitive, specific differentiation of acute and chronic HIV infection, but similar differentiation analyses have heretofore not been applied to HCV,” the researchers wrote.’

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

‘AbbVie ABBV, +0.92% a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin (RBV).’

Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment

‘People with HIV and hepatitis C co-infection were significantly more likely to experience organ rejection than people with hepatitis C alone or HIV alone after undergoing a liver transplant, according to a review of 11 years’ experience of liver transplantation in people with HIV and with hepatitis C virus (HCV) in the United States, published in advance online in the journal Clinical Infectious Diseases.’

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)